To our knowledge, this study represents the first population-based and focused on pre-ESRD population cohort analysis in Asia, a region characterized by a higher prevalence of CYP2C19 poor metabolizers, to assess the risk of renal-adverse events associated with PPI use in CKD patients. This evidence concerns the gene CYP2C19 and chronic kidney disease.